DEVELOPMENT OF SUSTAINED RELEASE BUPRENORPHINE FOR USE AS AN IMPROVEDANALGESIC IN TOXICOLOGY STUDIES: ASSESSMENT OF FORMULATION PHARMACOKINETICS

Abstract 502Poster 320

Koetzner, Lee1; Stokes, William2; Lance, William3; Wnorowski, Gary1; South, Natalie4; Boulet, Jamie11. Product Safety Labs, Dayton, NJ, US; 2. Kelly Services on behalf of NIEHS, Research Triangle Park, NC, US; 3. Wildlife Pharmaceuticals, Fort Collins, CO, US; 4. Battelle, Columbus, OH, US

ViV}>vii}Vi`iV>i>>>>``i1-i}>>}iVi>`i"iVi>`i`>``>i`Vi`i>V>iiiiviV>>}iV>`i`Vi>>``ivii>i}Vi`iiiiVi`i`>>iv>>}iVvVV}`iii]Liiii>vVi`>`}>i>>>ivviVi>>}i>`>iiviV`Vi`i>>i>i`ii>iv>`iiiiivivVii`>ivii`}/i>>ViVv>i`ii>iv>vLiiiiV>i`Lii>i}>ix} i>`7i>LL->i`ii>iv>iii>i`} i`i */>Vi>iiVi}LV>i`}]L`>iiiViVi`>i>v`>>>Lii>`iii`}`V>}>>iVii *>`/>Viv>`Vi`}i>>LiiVVi>>i>iv>>iv/i/>Viv>>ii`}iVVi>>i>ii]>i>VVi>i>>Li}p>VVi>i>V>i`>>}iV>ViiVip`}`i}>`v`ViiiV`i`]>```>`iiivviVvi>i>i`ii>iv> >L>VV>}V>iiiLii`/iii}}i>i/>Vi>i`ii>iv>vLiiV>}vV>i`Vii`}i>ii`>`V>Li>ivi>ViivVi`>i>i

Background and literature

>L>}>i>6i,i\{{i*i>V>L-Vx\n{

6

6ii`i>>i\,iVi`>viivV>>iiV]iV>>}iV>`>ii`>`i>>``iV>>vii} >>ii>V>L-Vx\"/i{x\Viii>V

ii>iv>>}iVV}`iii]Liii`L>>ViV]Vi>ii`v`}>LL>`i>L>>>iVi

7i>iii`>i`ii>iv>Vvviii>vVii``}

Conclusions

7i>i>Vii`>>i`Lii}vLV>LiV>i>V>i`ivvV>V

/i>i`Vi>iiiv`}iiv>iiVi

"v`}vi}vVv}i>ii-,/>Lv>Vi>iiiv`}

/iVL>v>i`>`>VvL>`iiivviV`V>i>i-,/>Lv>>>iv}i`}V}`ii}>>}iVivvV>Vvi`>

Results 2: Observations

>]Li>>V>}ii}vViii`>>i

}v>\iiqi`>iii>i *-,Liiq>i`ii>iv>-,/>LLiiq>i`ii>iv>v>

-LiV\{>i i>`L>LL]>x},L-iVi]i] >LLii``>i`i`i`>iiiiv>i`LV>}i]vi`>>/i>``i>`}i>i>`L

/i>i\>i>iii}i>LV>iiV}>}>}iii`i]>viV}v

->iViV\>iv>>iiiViVi`vii`>>ivii>>`>Vi`/Li>>>i>>i`LViv}>]i`>`i`vi

"Li>\>LLiii}i`]i``>vv`V]>`ViVi`Vi`>v}vv>>]Li>>V>}i}V

>\*Vi`iii>i`Li*-1>`V`Vi`>VV`>Vii*-*V>i>i>`1iv>L>>>`i1->7iv>iV*->>VVi`i`>L>

>>V>\

>Vqi>>`>`Lii{>`>``iii>``i`>i>`i>Vi`LV`i>`>Vii}>V>iii`i`>`iVi`vV>V`>i>`>Vii

>}>qiVii}>9"-+V>`->`*iVii>ii`iiVi`}>-Vi*xi`i,>q*i>iii}>i`>`>>i`}>{v>i

Materials and methods

Product Safety Labs

12 24 36 48 60 72 84 960.0

0.5

1.0

1.5

Baseline

Buprenorphine HCl (IR) 0.015 mg/kg

NMP-SR buprenorphine 0.1 mg/kg

Buprenorphine SRTM

-Lab 0.1 mg/kg

Time (vs. dose, hours)

C e

nih

pro

ner

pu

Bp

)L

m/g

n(

Results 1: Pharmacokinetics

ii>>VVi>ii`iii`vv}iV"ii`]i *v>i`ViLii>>>L]ii/>Viv>i`>>Li>>VVi>i>`iiVi1>i]V>V>i`viv1>`viiiiii1]>iLi}I]i>-

> 1 1ii xx {n *-,Lii x -,/>LLii x{ xnn

Results 3: Body weight and food consumption

vviiLiiv>ii>V>i`>L`i}V>}i>`v`ViLii`>iiiViV>Li>>L

`>i 7i}V>}i> `>{]} `>{]}ii {nn *-,Lii xn -,/>LLii x